Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it has received the approval from the National Medical Products Administration for clinical trial on FCN-338 tablets (the "Investigational New Drug") combined azacytidine or chemotherapy for the treatment of myeloid malignancies. Chongqing Fochon Pharmaceutical Research Co., Ltd. (Zhong Qing Fu Chuang Yi Yao Yan Jiu You Xian Gong Si) ("Fochon Pharma") (Shang Hai Fu Xing Yi Yao (Ji Tuan)Gu Fen You Xian Gong Si) (the "Investigational new Drug") combined azacytine or chemotherapy for the treatment ofMyeloid malignancies. Fochon Pharma intends to commence Phase II clinical trial for this indication in China (excluding Hong Kong, Macau and Taiwan Region for the purpose of this announcement, the same applies below) when the conditions are fulfilled.

Basic Information and Research Progress of the Investigational New Drug. The Investigational New Drug is a Bcl-2 selective small-molecule inhibitor self-developed by the Group which is intended to be used mainly for the treatment of hematological malignancies, recurrent or refractory B-cell lymphoma. As at the date of this announcement, the Investigational New Drug is at the stage of Phase I clinical trials in both China and the U.S. for the treatment of recurrent or refractory B -cell lymphoma.

As at The date of this announcement, the Bcl-2-targeted drugs approved for launch in China include VENCLEXTA®? (Wei Ke Lai®?) (Venetoclax Tablets) of AbbVie Inc. According to the data from IQVIA CHPA (provided by IQVIA, a professional information and strategic consulting service provider for the pharmaceutical and health industry, IQVIA CHPA data represents the drug sales market of hospitals with over 100 beds in China. The actual sales of different drugs may differ from the IQVIA CHPA data to varying degrees due to their different sales distribution channels), the sales of Bcl-2-targeting drugs in China amounted to approximately RMB 43.38 million in 2022.